Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
16.37
-0.86 (-4.99%)
At close: Feb 21, 2025, 4:00 PM
16.34
-0.03 (-0.18%)
After-hours: Feb 21, 2025, 7:05 PM EST
Mesoblast Employees
Mesoblast had 73 employees as of June 30, 2024. The number of employees decreased by 10 or -12.05% compared to the previous year.
Employees
73
Change (1Y)
-10
Growth (1Y)
-12.05%
Revenue / Employee
$80,849
Profits / Employee
-$1,204,877
Market Cap
2.15B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
MESO News
- 8 days ago - Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings - GlobeNewsWire
- 22 days ago - Ryoncil® Commercial Launch Update and Product Pipeline - GlobeNewsWire
- 22 days ago - Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024 - GlobeNewsWire
- 6 weeks ago - Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
- 2 months ago - Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges - Benzinga
- 2 months ago - Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy - GlobeNewsWire
- 2 months ago - US FDA approves Mesoblast's cell therapy for graft-versus-host disease - Reuters
- 2 months ago - Mesoblast to be Added to Nasdaq Biotechnology Index - GlobeNewsWire